BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

714

540797

SHALBY

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SHALBY LIMITED performance

Today’s low

Today’s high

₹ 215.01 ₹ 225.99
₹ 222.22

52 week low

52 week high

₹ 177.25 ₹ 274.70
₹ 222.22

Open Price

₹ 220.74

Prev. Close

₹ 220.93

Volume (Shares)

220989.00

Total traded value

₹ 491.08

Upper Circuit

₹ 265.11

Lower Circuit

₹ 176.74

info

SHALBY LIMITED Share Price Update

As of the latest trading session, SHALBY LIMITED share price is currently at ₹ 222.22, which is up by ₹ 1.29 from its previous closing. Today, the stock has fluctuated between ₹ 215.01 and ₹ 225.99. Over the past year, SHALBY LIMITED has achieved a return of 3.26 %. In the last month alone, the return has been -10.62 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SHALBY LIMITED fundamentals


  • Market cap (Cr)

    2,400.20

  • P/E Ratio (TTM)

    29.45

  • Beta

    0.93

  • Book Value / share

    109.23

  • Return on equity

    7.63%

  • EPS (TTM)

    7.52

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    19.75

info icon alternate text
  • Market cap (Cr)

    2,398.40

  • P/E Ratio (TTM)

    29.45

  • Beta

    0.86

  • Book Value / share

    109.23

  • Return on equity

    7.63%

  • EPS (TTM)

    7.52

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    19.75

info icon alternate text

SHALBY LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 223.97
Operating Expense 199.21
Net Profit 19.75
Net Profit Margin (%) 8.81
Earnings Per Share (EPS) 1.84
EBITDA 44.77
Effective Tax Rate (%) 35.37
Particulars JUN 2025 (Values in Cr)
Revenue 236.65
Operating Expense 202.07
Net Profit 25.70
Net Profit Margin (%) 10.85
Earnings Per Share (EPS) 2.39
EBITDA 52.36
Effective Tax Rate (%) 35.93
Particulars MAR 2025 (Values in Cr)
Revenue 207.06
Operating Expense 188.52
Net Profit 14.96
Net Profit Margin (%) 7.22
Earnings Per Share (EPS) 1.39
EBITDA 37.97
Effective Tax Rate (%) 41.74
Particulars DEC 2024 (Values in Cr)
Revenue 220.64
Operating Expense 191.15
Net Profit 20.86
Net Profit Margin (%) 9.45
Earnings Per Share (EPS) 1.94
EBITDA 48.80
Effective Tax Rate (%) 41.68
Particulars SEP 2024 (Values in Cr)
Revenue 212.27
Operating Expense 189.32
Net Profit 17.34
Net Profit Margin (%) 8.16
Earnings Per Share (EPS) 1.61
EBITDA 40.76
Effective Tax Rate (%) 38.71
Particulars MAR 2025 (Values in Cr)
Revenue 872.68
Operating Expense 763.38
Net Profit 83.79
Net Profit Margin (%) 9.60
Earnings Per Share (EPS) 7.80
EBITDA 185.74
Effective Tax Rate (%) 38.27
Particulars MAR 2024 (Values in Cr)
Revenue 829.68
Operating Expense 692.08
Net Profit 103.85
Net Profit Margin (%) 12.51
Earnings Per Share (EPS) 9.67
EBITDA 198.27
Effective Tax Rate (%) 34.40
Particulars MAR 2023 (Values in Cr)
Revenue 708.02
Operating Expense 606.03
Net Profit 80.81
Net Profit Margin (%) 11.41
Earnings Per Share (EPS) 7.52
EBITDA 161.51
Effective Tax Rate (%) 33.41
Particulars MAR 2022 (Values in Cr)
Revenue 646.80
Operating Expense 555.43
Net Profit 69.81
Net Profit Margin (%) 10.79
Earnings Per Share (EPS) 6.46
EBITDA 138.21
Effective Tax Rate (%) 30.13
Particulars MAR 2021 (Values in Cr)
Revenue 418.67
Operating Expense 372.78
Net Profit 42.88
Net Profit Margin (%) 10.24
Earnings Per Share (EPS) 3.97
EBITDA 95.74
Effective Tax Rate (%) 22.72
Particulars MAR 2025 (Values in Cr)
Book Value / Share 92.31
ROE % 0.19
ROCE % 6.08
Total Debt to Total Equity 0.43
EBITDA Margin 14.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 93.13
ROE % 8.66
ROCE % 11.59
Total Debt to Total Equity 0.29
EBITDA Margin 21.21
Particulars MAR 2023 (Values in Cr)
Book Value / Share 86.45
ROE % 7.50
ROCE % 10.33
Total Debt to Total Equity 0.19
EBITDA Margin 19.96
Particulars MAR 2022 (Values in Cr)
Book Value / Share 81.13
ROE % 6.31
ROCE % 8.85
Total Debt to Total Equity 0.12
EBITDA Margin 18.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share 77.28
ROE % 5.19
ROCE % 6.70
Total Debt to Total Equity 0.07
EBITDA Margin 22.37
Particulars MAR 2025 (Values in Cr)
Book Value / Share 105.50
ROE % 7.63
ROCE % 12.11
Total Debt to Total Equity 0.11
EBITDA Margin 21.46
Particulars MAR 2024 (Values in Cr)
Book Value / Share 98.89
ROE % 10.22
ROCE % 14.70
Total Debt to Total Equity 0.08
EBITDA Margin 24.07
Particulars MAR 2023 (Values in Cr)
Book Value / Share 90.42
ROE % 8.61
ROCE % 12.67
Total Debt to Total Equity 0.04
EBITDA Margin 23.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 83.95
ROE % 7.95
ROCE % 11.07
Total Debt to Total Equity 0.05
EBITDA Margin 21.62
Particulars MAR 2021 (Values in Cr)
Book Value / Share 78.66
ROE % 5.16
ROCE % 6.63
Total Debt to Total Equity 0.06
EBITDA Margin 23.09
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 34.86
Total Assets 1703.65
Total Liabilities 1703.65
Total Equity 995.32
Share Outstanding 107487005
Price to Book Ratio 1.88
Return on Assets (%) 0.36
Return on Capital (%) 0.44
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 27.22
Total Assets 1607.53
Total Liabilities 1607.53
Total Equity 1007.78
Share Outstanding 107412505
Price to Book Ratio 2.42
Return on Assets (%) 5.23
Return on Capital (%) 6.36
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 12.28
Total Assets 1281.36
Total Liabilities 1281.36
Total Equity 927.61
Share Outstanding 107309770
Price to Book Ratio 1.49
Return on Assets (%) 5.28
Return on Capital (%) 6.33
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 110.56
Total Assets 1193.53
Total Liabilities 1193.53
Total Equity 876.18
Share Outstanding 108009770
Price to Book Ratio 1.39
Return on Assets (%) 4.53
Return on Capital (%) 5.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 83.57
Total Assets 996.62
Total Liabilities 996.62
Total Equity 834.67
Share Outstanding 108009770
Price to Book Ratio 1.28
Return on Assets (%) 4.25
Return on Capital (%) 4.82
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 21.65
Total Assets 1469.80
Total Liabilities 1469.80
Total Equity 1133.99
Share Outstanding 107487005
Price to Book Ratio 1.88
Return on Assets (%) 5.70
Return on Capital (%) 6.77
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.22
Total Assets 1373.98
Total Liabilities 1373.98
Total Equity 1062.17
Share Outstanding 107412505
Price to Book Ratio 2.42
Return on Assets (%) 7.55
Return on Capital (%) 8.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.32
Total Assets 1165.65
Total Liabilities 1165.65
Total Equity 970.32
Share Outstanding 107309770
Price to Book Ratio 1.49
Return on Assets (%) 6.93
Return on Capital (%) 8.11
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 104.39
Total Assets 1087.38
Total Liabilities 1087.38
Total Equity 906.72
Share Outstanding 108009770
Price to Book Ratio 1.39
Return on Assets (%) 6.41
Return on Capital (%) 7.36
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 82.96
Total Assets 1012.25
Total Liabilities 1012.25
Total Equity 849.64
Share Outstanding 108009770
Price to Book Ratio 1.28
Return on Assets (%) 4.23
Return on Capital (%) 4.8
Particulars MAR 2025 (Values in Cr)
Net Income 55.72
Cash from Operations 9.89
Cash from Investing -35.63
Cash from Financing 47.58
Net change in Cash 7.60
Free Cash Flow 81.34
Particulars MAR 2024 (Values in Cr)
Net Income 128.19
Cash from Operations 39.66
Cash from Investing 38.07
Cash from Financing -150.69
Net change in Cash -93.02
Free Cash Flow 86.76
Particulars MAR 2023 (Values in Cr)
Net Income 102.04
Cash from Operations 96.18
Cash from Investing -61.07
Cash from Financing -50.00
Net change in Cash -43.30
Free Cash Flow 114.66
Particulars MAR 2022 (Values in Cr)
Net Income 79.14
Cash from Operations 41.90
Cash from Investing -60.30
Cash from Financing 90.45
Net change in Cash 49.07
Free Cash Flow 117.29
Particulars MAR 2021 (Values in Cr)
Net Income 55.05
Cash from Operations 88.24
Cash from Investing -51.26
Cash from Financing -29.85
Net change in Cash -1.97
Free Cash Flow 109.10
Particulars MAR 2025 (Values in Cr)
Net Income 135.74
Cash from Operations 160.23
Cash from Investing -100.62
Cash from Financing -35.79
Net change in Cash 12.39
Free Cash Flow 183.32
Particulars MAR 2024 (Values in Cr)
Net Income 158.31
Cash from Operations 159.53
Cash from Investing -206.00
Cash from Financing 72.13
Net change in Cash 5.90
Free Cash Flow 190.80
Particulars MAR 2023 (Values in Cr)
Net Income 121.35
Cash from Operations 191.59
Cash from Investing -172.40
Cash from Financing -38.21
Net change in Cash -46.08
Free Cash Flow 195.04
Particulars MAR 2022 (Values in Cr)
Net Income 99.92
Cash from Operations 123.73
Cash from Investing -40.31
Cash from Financing -17.24
Net change in Cash 43.36
Free Cash Flow 158.40
Particulars MAR 2021 (Values in Cr)
Net Income 55.49
Cash from Operations 86.48
Cash from Investing -51.83
Cash from Financing -27.82
Net change in Cash -2.41
Free Cash Flow 107.28
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7457.95 64.14 11.80 107233.88 6002.15 / 8099.00
FORTIS MALAR HOSPITALS LIMITED 64.77 26.76 3.53 121.39 52.31 / 98.70
SHREE PACETRONIX LTD. 263.20 44.24 5.64 102.65 61.11 / 283.15
TRANSGENE BIOTEK LTD. 3.65 0.00 3.00 27.66 3.21 / 8.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7457.95 76.50 11.51 107233.88 6002.15 / 8099.00
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 45.60 0.00 -13.25 34.06 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5970.75 28.58 5.48 6532.00 4810.20 / 6725.00

SHALBY LIMITED shareholding pattern

Holding

Others
20.84%
Promoter Holdings
74.32%
FII
4.63%
DII
0.19%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Shah Family Trust Throuh Dr. Vikram Shah, Trustee 3.7577132E7 (34.79%) Shareholding of Promoter and Promoter Group
Zodiac Mediquip Limited 3.1545448E7 (29.21%) Shareholding of Promoter and Promoter Group
Vikram Indrajit Shah 8005493.0 (7.41%) Shareholding of Promoter and Promoter Group
Darshini Vikram Shah 3012525.0 (2.79%) Shareholding of Promoter and Promoter Group
First Water Fund 1323577.0 (1.23%) Public Shareholding
Shanay Vikram Shah 137525.0 (0.13%) Shareholding of Promoter and Promoter Group
Uranus Medical Devices Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Eris Infrastructure Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shalby Orthopaedic Hospital And Research Centre 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Kairav Kirit Shah 250.0 (0.0%) Shareholding of Promoter and Promoter Group

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

News

Left Arrow
Right Arrow

SHALBY LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
222.22 0.58 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 224.30
  • 26 Days 235.00
  • 10 Days 227.90
  • 50 Days 234.00
  • 12 Days 229.30
  • 100 Days 225.70
  • 20 Days 233.40
  • 200 Days 222.10
222.42 PIVOT

First Support

217.86

First Resistance

225.50

Second Support

214.78

Second Resistance

230.06

Third Support

210.22

Third Resistance

233.14

RSI

34.11

ADX

19.36

MACD

-5.67

Williams % R

-95.17

Commodity Channel Index (CCI)

-116.52

Date

2025-11-19

Week

64685.00

Same Day

50028.00

Month

61920.00

1 Year

0.94

3 Year

1.16

Over 1 Month

-10.62%

down

Over 1 Year

3.26%

down

Over 3 Months

9.83%

down

Over 3 Years

15.41%

down

Over 6 Months

11.06%

down

Over 5 Years

19.54%

down

SHALBY LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2024 1.2 Final 20 Sep 2024 Equity shares
08 Aug 2023 1.2 Final 09 Aug 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
17 Sep 2021 1.0 Final 21 Sep 2021 Equity shares
04 Sep 2020 0.5 Final 08 Sep 2020 Equity shares
16 Aug 2019 0.5 Final 20 Aug 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2024 1.2 Final 20 Sep 2024 Equity shares
08 Aug 2023 1.2 Final 09 Aug 2023 Equity shares
19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
17 Sep 2021 1.0 Final 21 Sep 2021 Equity shares
04 Sep 2020 0.5 Final 08 Sep 2020 Equity shares
16 Aug 2019 0.5 Final 20 Aug 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Shalby Ltd share result highlights

For Q1 of FY 25-26, the company's consolidated sales were ₹296.43 crore, and its net profit for the period stood at ₹7.68 crore. In the corresponding Q1 of FY 24-25, the sales were ₹278.89 crore with a net profit of ₹14.74 crore for the period.

Date Source: screener.in, and corporate filings on NSE/BSE

Shalby Ltd share annual reports

For FY 24-25, the company reported consolidated sales of ₹1,087 crore and a net profit of ₹2 crore. In the preceding year, FY 23-24, the company's sales were ₹934 crore, and the net profit was ₹84 crore.

Date Source: screener.in, and corporate filings on NSE/BSE

Shalby Ltd share dividend

The company's stock has a face value of ₹10.00 per share and pays a dividend yield of 0.52%. The company has not yet declared any dividend for the current financial year, while it had announced a dividend for FY 2024-25 of ₹1.20 per share with ex-date of 19 September, 2024. 

Date Source: screener.in, and corporate filings on NSE/BSE

About Shalby Ltd 

Shalby Limited was originally incorporated as a private limited company in Ahmedabad on August 30, 2004, under the name 'Shalby Hospital Private Limited'. Over the following years, the company's corporate structure and name evolved to reflect its growth. In 2006, it was converted into a public limited company, and its name was changed first to 'Shalby Hospital Public Limited' and then to 'Shalby Hospitals Limited'. The company adopted its current name, Shalby Limited, in February 2008. The company operates a chain of multi-speciality hospitals headquartered in Ahmedabad, providing a range of medical and surgical services.

The hospitals in the Shalby network are primarily tertiary care facilities, with some units also offering quaternary care, which involves highly specialised treatments. While the organisation was founded by an orthopaedic surgeon, Dr Vikram Shah, and maintains a focus on orthopaedics and joint replacement surgeries, its service offerings have diversified to include multiple other specialisations. These include cardiology, neurology, oncology, critical care, and renal transplantations. Several of the company's hospitals have received accreditations that are benchmarks for quality in the Indian healthcare sector. Its hospitals in Ahmedabad (Krishna Shalby and SG Shalby), Indore, and Jabalpur are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH). Additionally, the Krishna Shalby and SG Shalby facilities have received accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL) for their laboratory services.

Shalby's network includes 11 multi-speciality hospitals and four specialist Shalby Orthopaedics Centres of Excellence (SOCE), which together have more than 2,000 beds. A network of 59 outpatient clinics in 16 states in India supports this physical infrastructure. These clinics serve as places for consultations and reaching out to patients. The company has also opened outpatient clinics in Kenya, Ethiopia, Tanzania, and Uganda, among other African nations, to expand its business internationally. These clinics in other countries are the first places patients go to get help, and they also make it easier for people to go to India for medical care.

The firm has grown in stages. After building its first facility, it constructed its first big multi-speciality hospital, SG Shalby, in Ahmedabad in 2007. Things kept getting better when a hospital opened in Vapi in April 2012 and another one, Krishna Shalby, opened in Ahmedabad in October 2012. In March 2015, the firm opened a hospital in Jabalpur, Madhya Pradesh, and in August 2015, it opened another one in Indore. Shalby has used an asset-light strategy to manage and run hospitals owned by other companies, such as its agreements for facilities in Mohali and Mumbai. This is in addition to building its own facilities.

The company made an Initial Public Offer (IPO) in December 2017 to get more money. This includes new equity shares and an offer to buy shares from a current shareholder. The money was supposed to assist in paying off debts and keep the business growing. In May 2021, Shalby made a huge strategic move by buying the assets of Consensus Orthopaedics, a California-based company that develops knee and hip implants. This purchase was a move towards vertical integration, which implies that the company now controls part of its supply chain for orthopaedic implants. In April 2020, the company backed this up by creating a fully owned subsidiary called Mars Medical Devices Limited.

Shalby has been getting bigger by buying other companies in the National Capital Region (NCR) and other regions during the past few years. It obtained a majority stake in PK Healthcare Pvt Ltd, which manages Sanar International Hospital in Gurugram, in the 2024 fiscal year. This turned it into a subsidiary. After that, it purchased Healers Hospital Pvt Ltd in Gurugram. The corporation held all of it. The company has also worked on employing new medical technologies. In 2022, it established a Digital Spine Operation Room at its Ahmedabad site and began delivering Video Assisted Thoracic Surgery (VATS). It has also improved its digital infrastructure, such as by adding a centralised, cloud-based Laboratory Information System (LIS).

Popular FAQs

Who is the CEO of Shalby?

The CEO of Shalby is responsible for leading the company’s strategic vision and overseeing its healthcare operations. Under their leadership, Shalby has continued to grow and expand its presence in the healthcare industry. The CEO’s focus on enhancing service quality and operational efficiency has contributed to the company’s positive financial performance, which has had a direct influence on the Shalby share price. Investors watch the CEO’s decisions closely to assess the company’s future prospects.
 

When was Shalby established?

Shalby was established several decades ago, entering the healthcare sector with a focus on providing quality medical services. Since its inception, the company has grown steadily, contributing to the rise in the Shalby share price. Over the years, Shalby has expanded its hospital network and diversified its service offerings, becoming a recognised name in the healthcare industry. The company’s establishment laid the foundation for its current success and continued market presence.
 

What factors influence the Shalby share price?

Several factors influence the Shalby share price, including the company’s financial performance, patient admissions, and operational efficiency. Internal factors such as revenue growth, profitability, and service expansion also play a critical role. External factors like industry trends, healthcare demand, and government policies further impact the share price. Investors carefully monitor these variables to assess potential movements in the Shalby share price and make informed decisions based on market and company performance.
 

Is Shalby debt free?

Shalby is not entirely debt-free but maintains a manageable level of debt that supports its growth and expansion plans. The company’s financial reports reflect that its debt levels are well-controlled and do not pose significant risks to its operations. This prudent debt management strategy positively impacts investor confidence and the Shalby share price, as the company continues to maintain financial stability while pursuing growth opportunities in the healthcare sector.
 

How has the Shalby share price performed over the past year?

The Shalby share price has experienced moderate fluctuations over the past year, influenced by the company’s financial performance and broader market conditions. While the share price saw periods of growth driven by strong earnings and hospital expansions, it also faced some volatility due to external factors. Overall, the Shalby share price has remained stable, reflecting the company’s solid position in the healthcare industry. Investors continue to monitor the company’s performance closely for future growth potential.

SHALBY LIMITED Share Price

Shalby Limited was originally incorporated as a Private Limited Company with the name 'Shalby Hospital Private Limited' on August 30, 2004. Subsequently, the Company was converted to a Public Limited Company and the name was changed to 'Shalby Hospital Public Limited' on May 15, 2006. Further, the name of the Company was changed to Shalby Hospitals Limited on July 26, 2006 and then, again changed to Shalby Limited on February 13, 2008.

Shalby Limited is an Ahmedabad-headquartered and one of the leading multi-specialty chain of hospitals in India and provides high-quality and economical healthcare services. With 15 hospitals and over 2,300 beds across 12 cities, Shalby is now the largest corporate hospital group in Western and Central India. The Hospitals are tertiary care hospitals, few of which offer quaternary healthcare services to patients in various areas of specialisation such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, and renal transplantations.

Led by Dr. Vikram Shah, an orthopaedic surgeon, the Hospital has grown from a single hospital to a chain of multi-specialty hospitals. Apart from orthopaedics, the hospitals provide advanced levels of care across various specialties such as neurology, cardiac care, critical care, oncology, and nephrology. The Hospitals, Krishna Shalby, SG Shalby, Shalby Indore and Shalby Jabalpur are accredited by the NABH. Further, Krishna Shalby and SG Shalby are also accredited by the NABL.

The Hospital currently runs a pan-Indian chain of 11 multispecialty tertiary hospitals and 4 Single specialty Hospitals (SOCE) across 6 states with a total bed capacity of more than 2,000. Shalby has 59 outpatient clinics (OPDs) across 16 states. It also expanded global presence by opening OPDs in Kenya, Nairobi, Ethiopia, Tanzania, and Uganda in the African continent.

In 2007, the Company established operations of its first multi-specialty hospital, SG Shalby, at Sarkhej Gandhinagar Highway in Ahmedabad.

The company commenced a new hospital Shalby Vapi at Vapi in April 2012 and thereafter it commenced a new hospital Krishna Shalby in Ahmedabad in October 2012.

The company commenced a new hospital Shalby Jabalpur at Jabalpur in Madhya Pradesh in March 2015. The company commenced a new hospital Shalby Indore at Indore in August 2015.

In 2016, the company executed a memorandum of understanding with ZH Private Limited to manage and operate Zynova Shalby. During the year under review, the company executed an O&M agreement with Kamesh Hospital to commence operations of Shalby Mohali.

In 2017, the company entered into an agreement with Bait Al Batterjee Medical Company LLC, Dubai, to provide outpatient orthopaedics and spine surgeries.

The Company came up with an Initial Public Offer of 20,354,838 Equity Shares by raising capital from public aggregating to Rs 504. 8 Crores comprising a Fresh Issue of 19,354,838 Equity Shares amounting to Rs 480 Crores and an Offer for Sale of 1,000,000 Equity Shares amounting to Rs 24.8 Crore in December, 2017.

With the increase in demand of digital transformation in healthcare sector, Shalby embarked its journey of digital transformation across its all hospitals from 2018-19. In 2020, the Company launched Video Assisted Thoracic Surgery (VATS) to reduce the incidence of surgical complications. The Liver Transplant Facility became fully operational at Shalby, Ahmedabad and Mohali.

The Company incorporated a new wholly owned subsidiary Company under the name and style Mars Medical Devices Limited' on April 3, 2020. The Company also incorporated wholly-owned subsidiary company under the name and style Shalby Hospitals Mumbai Pvt. Ltd.' on December 10, 2020. In May 2021, the Company acquired the assets of Consensus Orthopaedics, a hip and knee implant manufacturing company with its facility at El Dorado Hills, USA. The Company also commenced multi-speciality rehabilitation centre at one of its Unit in 2021.

The Company launched a state-of-the-art Digital Spine Operation Room' at SG Shalby Hospital, Ahmedabad in 2022. In September 2021, the Company launched its first Shalby Orthopedics Centre of Excellence (SOCE) in the country at Udaipur. Centralised cloud based Laboratory Information System (LIS) was launched in 2022. The Company further incorporated Shalby Advanced Technologies Inc. (SAT) in the first quarter of Fiscal 2022.

In 2022-23, the Company launched a new product line of Uni Knee System called as Tahoe Unicompartmental Knee System or TUKS.
It acquired 87.26% stake in PK Healthcare Pvt Ltd (Sanar International Hospital-130 beds) in FY 2024, making it a subsidiary of the Company and further acquired 100% stake in Healers Hospital Pvt Ltd at Gurugram costing Rs 104 Crore. Company further has established new SOCE in Ranchi having 60 beds in 2024.

The new Rajkot SOCE unit became operational from July 2024. The Company opened major units at Indore and other hospitals to strengthen the super-speciality capabilities, supported by the hiring of 40 doctors focused on high-end procedures. Sanar Shalby Hospital in Gurugram, enhanced a Centre of Excellence (CoE) for liver transplants, bone marrow transplants, CT transplants and complex procedures in FY 2025.

Parent organization Indian Private
NSE symbol SHALBY
Founded 2004
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Shalby Ltd?

Answer Field

Shalby Ltd share price is for NSE ₹ 222.22 & for BSE ₹ 222.45 as on Nov 20 2025 03:30 PM.

What is the Market Cap of Shalby Ltd Share?

Answer Field

The market cap of Shalby Ltd for NSE ₹ 2,388.57 & for BSE ₹ 2,391.04 as on Nov 20 2025 03:30 PM.

What is the 52 Week High and Low of Shalby Ltd?

Answer Field

The 52 Week High and Low of Shalby Ltd for NSE is ₹ 274.70 and ₹ 177.25 and for BSE is ₹ 274.50 and ₹ 177.20.

What is 1 year return for Shalby Ltd?

Answer Field

The 1 year returns on the stock has been 3.26%.

What is the P/E Ratio of Shalby Ltd Share?

Answer Field

As on Nov 20 2025 03:30 PM the price-to-earnings (PE) ratio for Shalby Ltd share is 29.45.

What is the PB ratio of Shalby Ltd Share?

Answer Field

As on Nov 20 2025 03:30 PM, the price-to-book (PB) ratio for Shalby Ltd share is 109.23.

How to Buy Shalby Ltd Share?

Answer Field

You can trade in Shalby Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Shalby Ltd Share on Bajaj Broking App?

Answer Field

To buy Shalby Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Shalby Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Shalby?

Answer Field

The CEO of Shalby is responsible for leading the company’s strategic vision and overseeing its healthcare operations. Under their leadership, Shalby has continued to grow and expand its presence in the healthcare industry. The CEO’s focus on enhancing service quality and operational efficiency has contributed to the company’s positive financial performance, which has had a direct influence on the Shalby share price. Investors watch the CEO’s decisions closely to assess the company’s future prospects.

When was Shalby established?

Answer Field

Shalby was established several decades ago, entering the healthcare sector with a focus on providing quality medical services. Since its inception, the company has grown steadily, contributing to the rise in the Shalby share price. Over the years, Shalby has expanded its hospital network and diversified its service offerings, becoming a recognised name in the healthcare industry. The company’s establishment laid the foundation for its current success and continued market presence.

What factors influence the Shalby share price?

Answer Field

Several factors influence the Shalby share price, including the company’s financial performance, patient admissions, and operational efficiency. Internal factors such as revenue growth, profitability, and service expansion also play a critical role. External factors like industry trends, healthcare demand, and government policies further impact the share price. Investors carefully monitor these variables to assess potential movements in the Shalby share price and make informed decisions based on market and company performance.

Is Shalby debt free?

Answer Field

Shalby is not entirely debt-free but maintains a manageable level of debt that supports its growth and expansion plans. The company’s financial reports reflect that its debt levels are well-controlled and do not pose significant risks to its operations. This prudent debt management strategy positively impacts investor confidence and the Shalby share price, as the company continues to maintain financial stability while pursuing growth opportunities in the healthcare sector.

How has the Shalby share price performed over the past year?

Answer Field

The Shalby share price has experienced moderate fluctuations over the past year, influenced by the company’s financial performance and broader market conditions. While the share price saw periods of growth driven by strong earnings and hospital expansions, it also faced some volatility due to external factors. Overall, the Shalby share price has remained stable, reflecting the company’s solid position in the healthcare industry. Investors continue to monitor the company’s performance closely for future growth potential.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59